Coherus matches Mylan on pegfilgrastim price

  
Generate a summary of this article
Listen to this article
Beta

Coherus BioSciences will match the US list-price discount offered by Mylan for biosimilar pegfilgrastim versus the reference brand when it begins shipping the firm's Udenyca (pegfilgrastim-cbqv) on 3 January 2019. Like Biocon's Fulphila (pegfilgrastim-jmdb) that partner Mylan launched earlier this year, Udenyca will be priced at US$4,175 per pre-filled syringe, a 33% discount to Neulasta's wholesale acquisition cost (WAC). "Beyond list price, we also have contracting plans that we believe will deliver additional value to payers, providers and patients in the long term, facilitating uptake," Coherus revealed.

Coherus BioSciences will match the US list-price discount offered by Mylan for biosimilar pegfilgrastim versus the reference brand when it begins shipping the firm's Udenyca (pegfilgrastim-cbqv) on 3 January 2019. Like Biocon's Fulphila (pegfilgrastim-jmdb) that partner Mylan launched earlier this year, Udenyca will be priced at US$4,175 per prefilled syringe, a 33% discount to Neulasta's wholesale acquisition cost (WAC). "Beyond list price, we also have contracting plans that we believe will deliver additional value to payers, providers and patients in the long term, facilitating uptake," Coherus revealed.

Speaking during the company’s third-quarter earnings call, Coherus’management indicated strongly that the company was, for now, prioritising pegfilgrastim efforts in...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Archive

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Prescribed Medications for Attention Deficit Hyperactivity Disorder) - Clone - Clone

 
• By Nabil

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.

Testing-Rising

 
• By Saba Afreen

Testing-Rising xxxx

bhvyuguig

lnkbkb

test 1

test 1

More from Generics Bulletin

GB-Business-Free-Podcast-The Secret to Walking More: It’s Not Counting Steps - Clone

 
• By Nabil

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.